BRAF, a target in melanoma

Cancer

Volumn 116, Issue 21, 2010, Pages 4902-4913

  Flaherty, Keith T ^a   McArthur, Grant ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

BRAF; Kinase inhibitor; Melanoma; Mutation; Oncogene

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; B RAF KINASE; CHIR 265; DASATINIB; GSK 2118436; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NILOTINIB; PLX 4032; SORAFENIB; UNCLASSIFIED DRUG; XL 281;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 78249254899     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25261     Document Type: Review

References (89)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949 -954.
2. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91: 355 -358.
3. Garnett MJ, Marais R,. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004; 6: 313 -319.
4. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116: 855 -867.
5. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009; 28: 85 -94.
6. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002; 62: 6997 -7000.
7. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003; 121: 1160 -1162.
8. Dummer R, Robert C, Chapman, PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study [abstract]. J Clin Oncol. 2008; 26 (May 20 suppl). Abstract 9033.
9. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88: 5399 -5404.
10. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95: 625 -627.
11. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002; 62: 6451 -6455.
12. Oliveira C, Pinto M, Duval A, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003; 22: 9192 -9196.
13. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003; 52: 706 -712.
14. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH,. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer. 2006; 119: 1858 -1862.
15. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95: 484 -486.
16. Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009; 27: 2129 -2136.
17. Knobbe CB, Reifenberger J, Reifenberger G,. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004; 108: 467 -470.
18. Ishimura N, Yamasawa K, Karim Rumi MA, et al. BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett. 2003; 199: 169 -173.
19. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A,. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene. 2003; 22: 4757 -4759.
20. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features [serial online]. PLoS Med. 2008; 5: e120.
21. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006; 30: 216 -222.
22. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353: 2135 -2147.
23. Tie J, Sieber O, Gibbs P, et al. Selecting subjects for a therapeutic target in colorectal cancer (CRC): using a clinical database to enrich for patients harboring the BRAF V600E mutation [abstract]. J Clin Oncol. 2009; 27 (suppl): 15S. Abstract 11003.
24. Hollestelle A, Nagel JH, Smid M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2009; 121: 53064.
25. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23: 6292 -6298.
26. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA,. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003; 63: 5198 -5202.
27. Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 2004; 23: 6031 -6039.
28. Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res. 1997; 3 (12 pt 2): 2696 -2702.
29. Packer LM, East P, Reis-Filho JS, Marais R,. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res. 2009; 22: 785 -798.
30. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004; 64: 2338 -2342.
31. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009; 15: 294 -303.
32. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP,. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003; 63: 2881 -2890.
33. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009; 41: 544 -552.
34. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003; 33: 19 -20.
35. Uribe P, Wistuba II, Gonzalez S,. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003; 25: 365 -370.
36. Uribe P, Andrade L, Gonzalez S,. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol. 2006; 126: 161 -166.
37. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC,. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol. 2008; 128: 2003 -2012.
38. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436: 720 -724.
39. Miettinen M, Sobin LH, Lasota J,. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29: 52 -68.
40. Padua RA, Barrass N, Currie GA,. A novel transforming gene in a human malignant melanoma cell line. Nature. 1984; 311: 671 -673.
41. van't Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989; 9: 3114 -3116.
42. Tsao H, Goel V, Wu H, Yang G, Haluska FG,. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004; 122: 337 -341.
43. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG,. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006; 126: 154 -160.
44. Daniotti M, Oggionni M, Ranzani T, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene. 2004; 23: 5968 -5977.
45. Cheung M, Sharma A, Madhunapantula SV, Robertson GP,. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008; 68: 3429 -3439.
46. Dai DL, Martinka M, Li G,. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005; 23: 1473 -1482.
47. Smalley KS, Contractor R, Nguyen TK, et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res. 2008; 68: 5743 -5752.
48. Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell. 2009; 33: 237 -247.
49. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, et al. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007; 26: 2856 -2867.
50. Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol. 2005; 166: 1069 -1075.
51. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005; 41: 1649 -1654.
52. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22: 6455 -6457.
53. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA,. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 1454 -1457.
54. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009; 101: 715 -721.
55. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099 -7109.
56. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of 4 phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007; 12: 426 -437.
57. Ratain M, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol. 2004; 22 (suppl): 14S. Abstract 4501.
58. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95: 581 -586.
59. Flaherty KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O'Dwyer PJ,. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma [abstract]. J Clin Oncol. 2005; 2 (June 1 suppl): 16S. Abstract 3037.
60. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009; 27: 2823 -2830.
61. Amiri P, Aikawa ME, Dove J, et al. CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations [abstract]. Proc Am Assoc Cancer Res. 2006; 47. Abstract 4855.
62. Schwartz GK, Robertson S, Shen A, et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors [abstract]. J Clin Oncol. 2009; 27 (suppl): 15S. Abstract 3513.
63. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C,. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008; 6: 751 -759.
64. Flaherty KT, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer [abstract]. J Clin Oncol. 2009; 27 (May 20 suppl): 15S. Abstract 9021.
65. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008; 105: 3041 -3046.
66. Puzanov I, Nathanson KL, Chapman PB, et al. PLX4032, a highly selective V600E BRAF kinase inhibitor: clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial [abstract]. J Clin Oncol. 2009; 27 (suppl); 15S. Abstract 9012.
67. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005; 23: 5281 -5293.
68. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007; 6: 2209 -2219.
69. Lorusso P, Krishnamurthi S, Rinehart JR, et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer [abstract]. J Clin Oncol. 2005; 23 (June 1 suppl): 16S. Abstract 3011.
70. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006; 439: 358 -362.
71. Smalley KS, Contractor R, Haass NK, et al. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer. 2007; 96: 445 -449.
72. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008; 26: 2139 -2146.
73. Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008; 14: 485 -493.
74. Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res. 2005; 11: 1983 -1989.
75. Krasilnikov M, Ivanov VN, Dong J, Ronai Z,. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene. 2003; 22: 4092 -4101.
76. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M,. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006; 5: 1136 -1144.
77. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24: 4764 -4774.
78. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329 -1338.
79. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104: 20932 -20937.
80. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68: 4853 -4861.
81. Owens DM, Keyse SM,. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 2007; 26: 3203 -3213.
82. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004; 101: 3130 -3135.
83. Bauer S, Duensing A, Demetri GD, Fletcher JA,. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007; 26: 7560 -7568.
84. V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008; 68: 7638 -7649.
85. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008; 7: 2876 -2883.
86. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004; 3: 1427 -1438.
87. Verhaegen M, Bauer JA, Martin de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006; 66: 11348 -11359.
88. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP,. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005; 65: 2412 -2421.
89. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y,. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006; 203: 1651 -1656.